Novartis lands capmatinib approval, giving them a second potential blockbuster from Incyte
Over a decade after Novartis promised Incyte up-to $1.1 billion for a pair of early stage drugs, the second of the two has crossed the finish line.
The FDA has granted accelerated approval to capmatinib, a pill for non-small cell lung cancers with a METex14 mutation. The drug, now branded as Tabrecta, is the first drug approved to target patients with that mutation, which now joins ALK, RET, ROS and EGFR on the list of non-small lung cancers that can be treated with targeted therapies. Novartis estimates around 4,000 to 5,000 patients are diagnosed with METex14 positive NSCLC each year, or around 3% to 4% of all NSCLC patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.